Detailseite
Projekt Druckansicht

Differenzierung und Aktivierung von Immunzellen im Tumormilieu - Analyse der Rolle von Laktat als Immunmodulator in vitro und in vivo

Fachliche Zuordnung Hämatologie, Onkologie
Förderung Förderung von 2011 bis 2018
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 190230491
 
Erstellungsjahr 2019

Zusammenfassung der Projektergebnisse

The tumor microenvironment modulates the activation of infiltrating cells and thereby regulates the balance between immune response and tolerance. The main findings of this project are that tumorderived lactic acid can suppress T and NK cells in vitro and in vivo which adds another piece to the tumor immune suppression puzzle. Based on these data we speculated that tumor derived lactic acid may limit the efficacy of checkpoint therapy. We demonstrated in several publications that the NSAID diclofenac blocks lactate secretion while preserving T cell effector functions which may result in a better response to checkpoint therapy. Our very recent data support this conclusion as we were able to show that diclofenac can improve checkpoint therapy in a murine breast carcinoma model. And we hope that these data will help us to get funding to confirm our findings in a clinical trial.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung